HeartFlow (HTFL) Q3 2026 Earnings Call Transcript
HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.
How this was made
The 30-second read
Why it matters
The guidance lift is likely to trigger buying interest, especially from investors focused on AI‑enabled medical technologies.
Market read
First‑report earnings guidance upgrade for HTFL, offering a clear catalyst for short‑term price movement.
What to watch
Potential reimbursement delays or competitive pressure from other imaging firms could temper upside.
Background
HeartFlow's Q3 2026 earnings call highlighted strong revenue growth, expanded Plaque adoption, and new collaborations, culminating in a significant guidance upgrade.
Ticker impact
HeartFlow raised its full-year revenue outlook to $262‑264M, up ~50% YoY, and lifted non‑GAAP gross margin guidance to ~82.5% in its Q3 2026 earnings call.
upward pressure as investors price in higher revenue and margin expectations
The guidance lift is material and the first report of these numbers, indicating improved growth outlook.
Market effects
Positive for cardiovascular imaging and AI‑driven diagnostic platforms, may boost peers in the cardiac CT space.
U.S. healthcare and AI sectors could see modest upside.
Limited to niche medical imaging market, but reinforces trend of AI integration in diagnostics.
Counterpoint
If guidance is overly optimistic, execution risk could lead to disappointment and a pull‑back.
Key entities
- CompanyHeartFlow
Cardiovascular imaging company providing AI‑driven Plaque and FFRCT analysis.
- CompanyBoston Scientific
Partner in CT‑guided PCI planning collaboration.
